C ell-surface and secreted glycoproteins and glycolipids contribute to numerous interactions with the extracellular environment that influence cellular physiology and pathology 1,2 . These interactions are strikingly diverse and include molecular recognition events that drive cell-surface signaling, cell adhesion, and modulation of receptor function, among others 2 . Terminal glycan structures also direct cellular targeting and clearance of circulating glycoproteins, including recombinant therapeutics, and define many pathogen and toxin tropisms 2 .
complex enzymatic reactions. Most notably, glycan elaboration is controlled by the availability, the abundance, and the specificities of the enzymes ('glycoenzymes') involved in glycan synthesis and catabolism 4 . Unlike RNA transcription and protein translation, these complex metabolic pathways are not template driven. Thus, the key to understanding glycan diversity and function lies in deciphering glycoenzyme specificities, structure-function relationships, and processes regulating their activities.
In mammals, ~700 enzymes and proteins contribute to glycan extension, modification, recognition, and catabolism 4 to generate the full collection of ≥7,000 vertebrate oligosaccharide structures 5 . These enzymes include ~200 GTs and ~80 GHs (Supplementary Data Sets 1 and 2) classified into 44 and 28 discrete sequence families, respectively, in the carbohydrate-active enzymes (CAZy) database 6 . Members of a given GT family generally have a common protein fold, but frequently have distinct acceptor substrate profiles and may have different sugar donor specificities 7, 8 . Thus, subtle structural differences between enzymes that display similar protein folds can produce glycoenzymes with unique catalytic specificities. These differences in substrate recognition among the GTs expressed in a given cell help determine the diversity of glycan structures in animal systems 4 .
Many challenges remain in advancing our understanding of vertebrate glycosylation machinery at a molecular level. Only a minor subset of the members in a given GT or GH family have been functionally characterized 6 , and structural studies have been performed on an even smaller subset of these enzymes. For mammalian glycoenzymes, these observations reflect challenges associated with their recombinant expression, as evidenced by the deposition of article NATure cheMIcAl bIoloGy dOI: 10.1038/nCHeMBIO.2539 only 28 of 202 vertebrate GT structures in the Protein Data Bank 6, 8 . A few mammalian GTs have been expressed in bacteria either as soluble truncated catalytic domains 9, 10 or with in vitro refolding 11 , but bacterial expression more commonly yields nonfunctional protein aggregates, as these enzymes require glycosylation, disulfide bonding, and chaperones that occur uniquely within the eukaryotic secretory pathway 12 . The most successful approach for recombinant glycoenzyme expression has been production in eukaryotic hosts, but this has been restricted to small-scale expression studies for relatively focused biochemical goals 8 . Broad access to large quantities of mammalian glycoenzymes would be greatly enhanced by the development of a unified, modular, high-throughput, and scalable expression platform.
We describe here an expression vector library encoding all known human glycoenzymes, comprising GTs, GHs, and sulfotransferases (STs), for production in either mammalian (HEK293) cells 13 or baculovirus-infected insect cells 14 . The strategy involved insertion of glycoenzyme coding cassettes into custom-designed plasmid or baculovirus expression vectors for recombinant production in mammalian or insect cells. We demonstrate successful expression and secretion of a large set of the glycoenzymes in mammalian cells and the baculovirus-insect cell system (65% secreted at ≥10 mg/L), generating quantities of the recombinant products sufficient for enzymatic and structural characterization and for glycan synthetic applications. We also demonstrate the purification of a subset of the GTs as a proof of concept, as well as complete enzymatic characterization and structural determination of the sialyltransferase ST6GalNAcII in complex with the donor analog, CMP. Thus, we demonstrate that the expression vector library and resulting recombinant products provide a substantial resource enabling detailed studies on these enzymes and a source of novel enzymatic tools for a wide array of biochemical and biomedical applications.
reSulTS

Strategies for fusion protein expression
A comprehensive list of 339 genes comprising all human GTs, GHs, and STs, as well as numerous other glycoenzymes was targeted for protein expression ( Supplementary Table 1 and Supplementary Data Set 1). This list included enzymes containing NH 2 -terminal or COOH-terminal transmembrane domains (TMDs), multipass enzymes with internal TMDs, enzymes with NH 2 -terminal signal sequences, and cytosolic enzymes with no TMD or signal peptide. A modular design strategy was used to transfer full-length or truncated enzyme (catalytic domain) coding regions into custom, host-specific expression vectors by Gateway recombination 15 (Fig. 1 and Supplementary Figs. 1-3) . NH 2 -or COOH-terminal transmembrane segments, NH 2 -terminal signal sequences, or COOH-terminal endoplasmic reticulum (ER) retention sequences 16 were generally deleted and replaced by a tobacco etch virus (TEV) protease recognition and cleavage site sequence 17 . The resulting coding regions were then flanked with Gateway recombination site sequences and transferred into a plasmid vector backbone to form a library of Gateway glycoenzyme 'donor' clones ( Fig. 1 and Supplementary Fig. 1) .
Custom expression vectors included host-specific promoter elements, in-frame fusion tags, and complementary Gateway recombination sites (Gateway destination "DEST" vectors; Fig. 1 and Supplementary Figs. 2 and 3) . Recombination of the Gateway donor clones harboring target gene coding regions with hostspecific DEST vectors yielded the final expression vector construct library, containing host-specific transcription and translation elements that drive the recombinant production of target proteins with vector-encoded fusion tags. For example, mammalian DEST vectors included a human cytomegalovirus (CMV) promoter; fusion tag sequences; Gateway recombination and selection sequences; and artificial intron, enhancer, termination, and polyadenylation sequences. Upon Gateway recombination with the donor clones, the Gateway recombination and selection cassette was replaced with the glycoenzyme coding sequence, fusing it in-frame with the vectorencoded tag sequences ( Supplementary Figs. 2 and 3) . Three vectors appended different combinations of NH 2 -terminal fusion tags (pGEn1 contained a signal sequence 18 , an 8×His tag, and a StrepII tag 19 ; pGEn2 contained a signal sequence, an 8×His tag, an AviTag 20 , and a GFP domain 21 ; pGEn3 contained a signal sequence, an 8×His tag, a GFP domain and an IgFc domain 22 ; Supplementary Fig. 2) , and two other vectors appended different combinations of COOHterminal fusion tags (pGEc1 contained an 8×His tag and a StrepII tag; pGEc2 contained a GFP domain, an AviTag, and a 8×His tag; Supplementary Fig. 2) . Thus, various expression vectors enabled Glycogene N-term TEV fusion gateway donor constructs Glycogene C-term TEV fusion gateway donor constructs 
Figure 1 | Flow chart for generation of glycoenzyme expression constructs.
General workflow for generating the human glycoenzyme expression constructs is depicted using a master glycogene list (Supplementary Data Set 1) and truncation designs based on tMd sequences, cleavable signal sequences, and available knowledge regarding the location of the enzyme active sites. coding regions were incorporated into Gateway 'donor' vectors by pcR from cdnA sources or gene synthesis, and a tev protease recognition site was appended on either the nH 2 -or cooH-terminal end of the coding region ( Supplementary Fig. 1 ). thus, a library of all human glycoenzyme constructs ('glycogenes') in donor vectors was generated for Gateway lR recombination into custom mammalian or baculovirus deSt vectors harboring additional in-frame fusion tags (Supplementary Figs. 2 and 3) and employed to produce glycogene expression constructs for each recombinant host system. expression and secretion of recombinant enzymes were examined by batch-mode transient transfection (HeK293 cells) or baculovirus infection (insect cells), and secreted products were used to produce enzyme preparations with utility for enzymology, structural studies, enzymatic glycan synthesis and numerous other applications.
article NATure cheMIcAl bIoloGy dOI: 10.1038/nCHeMBIO.2539 transfer of each glycoenzyme coding region into multiple NH 2 -or COOH-terminal fusion protein contexts. We also generated custom Gateway-adapted baculovirus expression vectors (BEVs) with polyhedrin promoters that supported fusion strategies analogous to the mammalian expression plasmids (Supplementary Fig. 3 ). Thus, two BEVS supported NH 2 -terminal fusion strategies similar to those of the pGEn1 and pGEn2 vectors, and an additional BEV provided a COOH-terminal fusion strategy similar to the pGEc1 vector. The same glycoenzyme donor clones were used for recombination into both the mammalian and baculovirus expression constructs to produce a parallel set of vectors for expression of NH 2 -terminal or COOH-terminal fusion proteins in the two recombinant hosts.
Target protein expression, secretion, and quantitation
Glycoenzyme production and secretion efficiency was initially tested in HEK293 cells using the NH 2 -terminal fusion vectors (pGEn1, pGEn2, and pGEn3) and fourteen GT29 sialyltransferase coding regions ( Supplementary Fig. 4) . The pGEn2 and pGEn3 vectors harboring the GFP fusion domain resulted in secretion of fusion proteins at higher levels than that observed with pGEn1, which did not contain this domain. Thus, pGEn2 was chosen for further screening of NH 2 -terminal GFP fusion proteins, and pGEc2 was used for the COOH-terminal GFP fusions. Because generation of most of the BEV stocks was underway well before we determined that the GFP fusion cassette was the preferable strategy for the mammalian expression vectors, screening efforts using BEVs GALNT1  GALNT2  GALNT3  GALNT4  GALNT5  GALNT6  GALNT7  GALNT8  GALNT9  GALNT10  GALNT11  GALNT12  GALNT13  GALNT14  GALNT15  GALNT16  GALNT17  GALNT18  GALNT19  GALNT20  ST3GAL1  ST3GAL2  ST3GAL3  ST3GAL4  ST3GAL5  ST3GAL6  ST6GAL1  ST6GAL2  ST6GALNAC1  ST6GALNAC2  ST6GALNAC3  ST6GALNAC4  ST6GALNAC5  ST6GALNAC6  ST8SIA1  ST8SIA2  ST8SIA3  ST8SIA4  ST8SIA5  ST8SIA6  B3GALNT1  B3GALNT2  B3GALT1  B3GALT2  B3GALT4  B3GALT5  B3GALT6  B3GLCT  B3GNT2  B3GNT3  B3GNT4  B3GNT5  B3GNT6  B3GNT7  B3GNT8  B3GNT9  C1GALT1  C1GALT1C1  CHPF  CHPF2  CHSY1  CHSY3 LFNG MFNG RFNG
Figure 2 | expression and secretion of the glycoenzyme constructs in mammalian cells.
(a) the full collection of 339 human glycoenzymes as nH 2or cooH-terminal GFp fusion proteins was expressed in HeK293 cells, and fusion protein production and secretion was profiled. protein-coding regions were clustered by transmembrane topology and truncation strategy, including enzymes harboring nH 2 -terminal tMds, which were truncated to delete the transmembrane sequences and replaced with an nH 2 -terminal fusion tag (type ii tMd (truncated)); those harboring an nH 2 -terminal signal sequence (n-terminal signal sequence), which were designed for protein fusions as described in online Methods; proteins containing cooH-terminal tMds (type i tMd (truncated)), which were truncated to delete the tMd and replaced with a cooH-terminal fusion tag; and cytosolic and multipass tMd enzymes, which were expressed as full-length coding regions containing cooH-terminal fusions. total GFp fluorescence (cells + media) and cell-free media fluorescence values were converted into milligram quantities of fusion protein per liter and used to assess the efficiency of fusion protein secretion (% secretion). the order of the genes in each clustered transmembrane topology category was based on the rank order of overall (cell + media) expression (yellow circles). the corresponding quantity of secreted fusion protein for each coding region is indicated as blue squares. For each protein coding region, the efficiency of fusion protein secretion (% secretion) was indicated in the upper panel (gray circles). (b) For examination of the relative expression and secretion levels within individual Gt sequence families, the values of secreted (blue bars) and cell-associated (pink bars) fusion proteins for individual polypeptide GalnAc transferases (Gt27 ppGalnAct), Sialyltransferases (Gt29 Sialylt), and galactosyltransferases/N-acetylglucosaminyltransferases (Gt31 Gal/GlcnAct) are displayed as stacked bar graphs with the respective gene name listed below each bar. upper panel shows the efficiency of fusion protein secretion (percent secretion) for each coding region (gray circles). Fluorescence values for the secreted sialyltransferases were ± 10% of the indicated values in cases where replicate transfection experiments were performed (n =3).
article NATure cheMIcAl bIoloGy dOI: 10.1038/nCHeMBIO.2539 focused on the short NH 2 -terminal fusion vector, analogous to pGEn1 ( Supplementary Fig. 5 and Supplementary Data Set 1). Protein expression was profiled by immunoblotting with antibodies that recognize the His-tag appended to the target enzymes. The GFP fusion domain also facilitated protein quantitation during expression and purification (Figs. 2 and 3; Supplementary Figs. 4 and 6; Supplementary Data Set 1). Overall protein expression levels in mammalian cells were ≥10 mg/L for 94% of the recombinant products ( Fig. 2) , whereas 65% of the fusion proteins designed for secretion were secreted at levels of ≥10 mg/L. Surprisingly, there was no apparent correlation between expression levels and secretion efficiencies ( Fig. 2a) . To illustrate this variability, we examined twenty GT29 sialyltransferases that were designed using identical truncation and fusion strategies. Fluorescence measurements ( Fig. 2b) and SDS-PAGE ( Supplementary Fig. 5 ) indicated a subset of the enzymes (ST6GalI, ST3GalI, ST3GalIII, and ST3GalIV) that were exceptionally well expressed, as well as others that were well expressed but poorly secreted (ST3GalV), poorly expressed (ST3GalVI and ST6GalNAcIII), or expressed and secreted but subject to proteolysis (for example, ST6GalII and ST6GalNAcI; Supplementary Fig. 5 ). Similar variations in protein expression and secretion were also seen within other protein families (for example, GH27 and GT31 in Fig. 2b and Supplementary Data Set 1).
comparison of insect and mammalian cell expression
A comparison of protein expression and secretion in mammalian and BEV-infected insect cells revealed similar trends ( Fig. 3a) . However, there was considerable scatter in the data, indicating that one of the two expression hosts was more effective for expression of some individual coding regions. As the initial expression screening employed different fusion protein strategies for the two host systems, we generated BEVs encoding twenty GT29 sialyltransferases with NH 2 -terminal GFP fusions for direct comparison with equivalent mammalian expression constructs ( Fig. 3b and Supplementary  Fig. 5b ). GFP fluorescence data demonstrated that protein-secretion efficiencies were quite variable in both hosts, but secreted protein levels were highly correlated for half of the fusion proteins across the two recombinant hosts (R 2 = 0.99; Fig. 3b ). In contrast, eight of the sialyltransferase fusion proteins were more highly secreted in mammalian cells, and two were more highly secreted in the BEVs (Fig. 3b) . Thus, the observations were similar to the expression data for the larger collection of the glycoenzymes (Fig. 3a) : a subset of proteins was more effectively secreted in either human or insect cells, but most were secreted at similar levels in the two different expression hosts.
Purification of human glycoenzymes
To demonstrate purification of enzymes from both expression hosts, we used immobilized metal affinity chromatography (IMAC) to isolate the 8×His tagged sialyltransferase fusion proteins from mammalian and insect cell-free media. The results showed effective purification of even some of the more poorly expressed proteins after scale-up ( Supplementary Fig. 6 ). In the mammalian host, a majority of the GT29 sialyltransferases were able to be purified at >10 mg/L of transfected cell culture, indicating that these enzymes could be produced and purified at levels required for biochemical and structural studies.
Structure determination of human ST6GalNAcII
To demonstrate the utility of the expression vector library for glycoenzyme characterization, we scaled up production of one of the sialyltransferase GFP fusions (ST6GalNAcII-pGEn2) in HEK293S (GnTI -) cells 23 using a selenomethionine labeling protocol established in prior structural studies 24 . IMAC purification of the secreted fusion protein, in vitro cleavage with TEV protease and endoglycosidase F1 (EndoF1), and further 
Figure 3 | comparison of secreted enzyme expression in transfected mammalian cells and baculovirus-infected insect cells.
(a) the collection of human glycoenzymes was expressed using mammalian expression vectors or bevs in each respective host, and protein secretion levels were compared. For mammalian cell expression, the pGen2 or pGec2 GFp fusion vectors were employed, and secreted recombinant products were quantified by GFp fluorescence (y axis values for blue diamonds). For bev expression, the shorter His-and Strepii-tagged constructs (Short n-term fusions; Supplementary Fig. 3) were employed, and the respective secreted fusion proteins were quantified using anti-His-tag immunoblots. the semiquantitative immunoblot intensities (Supplementary Data Set 1) were converted into arbitrary relative intensity values (x axis values for blue diamonds) and compared with the values for enzyme secretion in mammalian cells in a two-dimensional dot plot. the mean and s.d. for the GFp fluorescence values are indicated by the thick red bar and error bars. A trend line is shown for the mean values for GFp fluorescence (red dotted line). (b) As the fusion protein strategy was different in the mammalian and bev constructs, a subset of the constructs comprising the twenty Gt29 sialyltransferases was generated in the GFp n-terminal fusion baculovirus ( Supplementary Fig. 5 ) for direct comparison with the equivalent pGen2 mammalian GFp fusion constructs. comparison of secreted GFp fluorescence values indicated a close correlation for a subset of ten sialyltransferases (blue diamonds; trend line indicated with R 2 = 0.99), whereas eight were more highly secreted in mammalian cells (red squares), and two were more highly secreted in bevS (green triangles). Anti-His tag western blots of the equivalent samples for the Short n-term tag (no GFp tag) and the GFp n-term fusion baculovirus constructs are shown in Supplementary Figure 5 . Fluorescence values for the secreted sialyltransferases were ± 10% of the indicated values in cases where replicate transfection experiments were performed (n = 3). purification yielded the ST6GalNAcII catalytic domain devoid of all tag sequences, with N-glycans trimmed to a single GlcNAc residue ( Supplementary Fig. 7) . Kinetic parameters for the TEV/EndoF1-cleaved ST6GalNAcII and the GFP fusion protein were similar (Supplementary Table 2 ), indicating that the GFP fusion did not alter enzyme activity. The structure of the catalytic domain was determined to 3.1 Å resolution by single-wavelength anomalous diffraction (SAD) phasing ( Supplementary  Table 3 ), and additional diffraction data were obtained to 2.35 Å for a complex of ST6GalNAcII with the donor analog, CMP ( Fig. 4 and Supplementary Table 3 ). The structure revealed a single Rossmann-like (GT-A variant 2) fold similar to those of other known GT29 sialyltransferases 9,24-26 with highly conserved 'sialylmotif ' sequence elements 27, 28 comprising the core of the protein fold ( Supplementary Figs. 8-10 ). The bound CMP was clearly evident in the electron density at a position equivalent to other sialyltransferases ( Fig. 4 and Supplementary Fig. 10 ), confirming conservation of the sialylmotif scaffold underlying the Supplementary Fig. 9 ). there are six protomers in the crystallographic asymmetric unit, and some of the units contain disordered loops of varying lengths. (a-d) images represent chain c, which contains a 7-residue disordered loop between helix α5 and strand β1 (magenta line in c and Supplementary Fig. 9 ). (a) view from the top of the active site, where the bound donor analog, cMp, is shown in yellow stick representation. (b) Surface representation in the same orientation as in a. (c) cartoon representation of the protein structure at a 90° rotation relative to that in a. the position of the His351 residue, the predicted catalytic base in the structure by comparison to structures of other Gt29 sialyltransferases 24 , is shown in cyan stick representation. Weak electron densities for monosaccharide residues were found to be extended from the amide side chains of Asn85, Asn130, and Asn161, as predicted for each residue found within an nxS glycosylation sequon (where x is any amino acid except pro). the positions of the respective Asn side chains are indicated by white stick representations, and magenta spheres represent the amide nitrogens where the n-glycan is attached. Four cys residues are found in the structure, with each participating in a disulfide bond. the nH 2 terminal residue in the structure, cys66, is disulfide bonded to cys148, while a disulfide bond links cys151 with cys317 (white stick representations with yellow sulfur atoms shown as spheres). (d) extensive interactions were identified between the bound cMp donor analog and the binding site, including polar interactions (green dotted lines) and a hydrophobic stacking with phe325.
article NATure cheMIcAl bIoloGy dOI: 10.1038/nCHeMBIO.2539 CMP-Neu5Ac binding site 24 . Substantial differences relative to other sialyltransferase structures were found outside the sialylmotif elements ( Supplementary Fig. 10 ), reflecting the minimal primary sequence or structural similarity among the sialyltransferases in the loop regions and secondary structure elements involved in acceptor substrate recognition. While structures have been reported for three of the four vertebrate GT29 sialyltransferase subfamilies that generate Neu5Ac-α2,6Gal 24, 25 , Neu5Ac-α2,3Gal 9 , and Neu5Ac-α2,8Neu5Ac 26 linkages, the present ST6GalNAcII structure is the first reported for a Neu5Ac-α2,6GalNAc subfamily member 24 (Supplementary Fig. 8 ). This proof of principal for the cloning, expression, biochemical analysis, and structure determination pipeline will be the basis of further studies to explore the structural basis of acceptor recognition for ST6GalNAcII.
DIScuSSIoN
Diversity in vertebrate cell surface and secreted glycan structures is generated in complex biosynthetic pathways 1, 2, 4 . The overall purpose of this study was to produce an expression vector library enabling the production of 339 enzymes involved in human glycan synthesis, modification, and catabolism for enzymatic, structural, and functional studies. We initially determined that Escherichia coli was not an appropriate host for these recombinant enzymes, and as a result we focused on expression in mammalian and insect cell hosts, which are amenable to high-throughput profiling of protein expression and production that can be scaled up to larger culture volumes 13, 14 .
A variety of fusion tag strategies were tested. Inclusion of the 'superfolder' GFP domain improved protein production and secretion for many GTs tested in both human and insect cell systems ( Supplementary Figs. 4 and 5) compared to the shorter fusion tags. The GFP fusion also facilitated detection and quantitation of recombinant products during expression and purification. Thus, all glycoenzymes were initially profiled as GFP fusions in HEK293 cells.
Most of the glycoenzyme fusion constructs were highly expressed in HEK293 cells, and a major subset (~65%) was well secreted and able to be purified at multimilligram levels from the culture media. The efficiency of secretion was surprisingly variable and did not correlate with overall expression level, transmembrane topology, or enzyme family. This variability was highlighted for the GT29 sialyltransferases, but was also observed with other GT families. These data suggest that each protein coding region has a unique set of folding constraints within the eukaryotic secretory pathway that cannot be generalized more broadly, even within an enzyme structural family.
Parallel expression studies were performed using BEV-infected insect cells, and the trend in overall expression and secretion level was similar to that in transfected mammalian cells. When enzymes with equivalent tags were compared, half were secreted at comparable levels by the two hosts, whereas the remainder were more highly secreted by either mammalian or insect cells. These data suggest that host-specific factors can also contribute to secretion efficiency for some recombinant products.
Other factors can also contribute to the efficiency of protein production in eukaryotic cells. In vivo, many full-length GTs are transmembrane proteins that can assemble into homodimers or heterooligomeric complexes with other proteins 29 . Sequences proximal to the TMD can also play roles in oligomer formation 30 . Thus, removal of the proteins from their transmembrane contexts and the lack of co-expression with binding partners may contribute to difficulties in folding or secretion. Nevertheless, >65% of the GTs were efficiently expressed as single coding regions in the absence of their TMDs.
Overall, most of the glycoenzymes designed for secretion can be readily purified from the culture media at high yields using IMAC ( Supplementary Fig. 6 ). In addition, kinetic analysis was performed on several of these purified recombinant products before and after tag removal with TEV protease. The results, exemplified by ST6GalNAcII (Supplementary Table 2) , indicated that the GFP fusion proteins and catalytic domains released had comparable activity 24, 31 . To illustrate the utility of the expression library, we characterized several of the GTs, revealing enzyme substrate [31] [32] [33] [34] [35] [36] [37] or chaperone 38 specificities, and corrected the glycan linkage synthesized by a GT 39 . We also used some products for chemoenzymatic synthesis of novel glycan structures [40] [41] [42] [43] and selective exoenzymatic labeling (SEEL) [44] [45] [46] of cell-surface glycans. These efforts demonstrated the utility of our expression vector library for various glycoenzyme studies and for direct applications in glycobiology.
As a proof of concept for the utility of the HEK293 platform in protein structural studies, we focused on ST6GalNAcII, an enzyme that adds α2,6-linked Neu5Ac to the GalNAc residue on Core 1 O-glycans 47 . These studies established a unified and scalable workflow for production and purification of the glycoenzymes for both enzymatic and structural studies. As the expression vector library was being completed, we continued to expand the application of the workflow for structural studies on the extracellular domain of a calcium-sensing receptor with a novel bound ligand 48 and a plant xyloglucan fucosyltransferase 49 . We also continue to apply similar approaches to study additional human glycosyltransferase structures. Thus, it is clear the constructs, expression systems, and workflows for glycoenzyme production and purification described here will reveal new insights into substrate recognition and catalysis for this diverse and important set of glycoenzymes and provide transformative reagents that will continue to expand our knowledge in glycochemistry and glycobiology. 
MeThoDS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
references oNlINe MeThoDS
Choice of protein-coding regions for recombinant expression. A comprehensive list of human glycoenzymes was identified in prior efforts to profile glycogene transcription in mouse cells 4 . Starting with this comprehensive list of >700 glycogenes, we targeted 339 coding regions to generate expression constructs comprising all known human GTs involved in glycan extension, GHs involved in glycan catabolism and processing, STs involved in glycan modification, as well as a collection of additional genes involved in glycan elaboration, modification, or catabolism (Supplementary Data Set 1).
Truncation and fusion protein strategies for glycoenzyme expression. Each glycoenzyme coding region on the target list was examined for sequence features in the UniProt database 50 to determine the presence of TMDs, NH 2terminal signal sequences, COOH-terminal KDEL ER retention sequences 16 , or known catalytic residues. In general, proteins containing NH 2 -terminal TMDs (type II transmembrane proteins) were designed to truncate all sequences spanning from the initiating Met residue to the first charged residues at the luminal boundary of the TMD. These proteins were all designed as NH 2 -terminal fusions to a TEV protease recognition peptide sequence 17 during transfer to Gateway donor vectors ( Supplementary Fig. 1 and Supplementary Data Sets 1 and 2). Proteins containing COOH-terminal TMDs were designed to truncate the TMD between the first charged residue on the luminal side of the TMD and the COOH-terminus of the protein (Supplementary Fig. 1) . A TEV protease recognition sequence was appended to the COOH-terminus of the coding region during transfer to the Gateway donor vector ( Supplementary  Fig. 1 ). Proteins containing NH 2 -terminal signal sequences were generally designed as full-length coding regions with a COOH-terminal TEV site extension added in place of the termination codon during transfer to the Gateway donor vectors. Many of these latter enzymes were also designed to truncate the NH 2 -terminal signal sequence with a subsequent NH 2 -terminal fusion with the TEV recognition site sequence (Supplementary Data Set 1). Proteins containing multipass TMDs, internal TMDs, or soluble cytosolic proteins were generally designed as full-length coding regions and had a COOH-terminal TEV extension added in place of the termination codon during transfer to the Gateway donor vectors (Supplementary Data Set 1). In some of these latter cases NH 2 -terminal TEV fusions were also generated to test alternative tagging strategies for protein expression.
Isolation of protein coding regions and capture as Gateway donor clones.
Three strategies were employed to isolate full length or truncated protein coding regions with appropriate TEV protease cleavage site fusions and flanking attL recombination sites in Gateway donor vectors. First, full-length human cDNA clones were identified within the Mammalian Gene Collection (MGC) 51 , and plasmid DNAs encoding each respective coding region were used as templates for gene-specific PCR amplification. Gene-specific primer sequences were synthesized (Eurofins MWG Operon, Louisville, KY) as shown in Supplementary  Figure 1 , with 5′ extensions to initiate the synthesis of the attB recombination and TEV protease recognition sites based on the design for truncation and fusion. PCR amplification products were generated using 0.1 μM gene-specific primers, 100 ng plasmid DNA, and AccuPrime Pfx DNA Polymerase (Thermo Fisher Scientific) in a total volume of 50 μl. PCR conditions were as follows: denaturation at 94 °C for 2 min followed by 15 PCR cycles comprised of 94 °C denaturation for 15 s, annealing at 57 °C for 1 min and extension at 68 °C for 2 min. After the first round of amplification, 20 μl of the gene-specific PCR reaction was then subjected to a second round of amplification using a pair of universal primers and identical PCR reaction conditions as those described above to complete the synthesis of the attB sites as indicated in Supplementary  Figure 1 . PCR products were then used directly for Gateway recombination with the pDONR221 vector in BP Clonase II reactions with a final volume of 10 μl, as described by the manufacturer (Thermo Fisher Scientific). The reaction products were transformed into the 5-alpha competent E. coli strain (New England BioLabs, Ipswich, MA), and plated on LB plates containing kanamycin. The resulting plasmid clones were screened by restriction mapping and verified by DNA sequencing of the entire coding region.
For genes that were not available in MGC or were not successfully amplified from MGC clone templates, an alternative amplification approach was employed. A library of human RNAs (FirstChoice Human RNA Survey Panel, Thermo Fisher Scientific) was reverse transcribed using 500 ng RNA, a mixture of random hexamers and oligo (dT) 20 primers and a reaction mix supplied with the SuperScript II First Strand Synthesis System, as described by the manufacturer (Thermo Fisher Scientific). Test amplifications were performed using respective gene-specific primers, the human cDNAs, and Phusion DNA polymerase reaction mix (Thermo Fisher Scientific) as described above. Annealing temperatures, extension times, primer concentrations, and cycle numbers were varied to identify optimal conditions for PCR amplification of the predicted coding region. Once optimal primary amplification conditions were identified, the resulting PCR products were purified using a QiaQuick PCR purification kit (Qiagen) and subjected to a second round of amplification as described above using the universal primers shown in Supplementary  Figure 1 . Second round amplification products were isolated using the QiaQuick PCR purification kit, subjected to Gateway BP Clonase recombination into the pDONR221 vector, and transformed into 5-alpha competent E. coli as described above. The resulting plasmid clones were verified by DNA sequencing of the entire coding region.
In instances where amplification of coding regions from MGC or cDNA sources was unsuccessful, or when coding regions were poorly expressed, the coding regions were generated by gene synthesis. Coding region designs containing TEV fusion sequences and flanking attL1 and attL2 recombination sites (Supplementary Data Sets 1 and 2) were synthesized with human codon optimization (GeneArt gene synthesis, Thermo Fisher Scientific) and subcloned into a vector backbone containing a kanamycin resistance marker (pMK-RQ). The gene synthesis products in this vector backbone were equivalent to the pDONR221 constructs and were used directly for recombination into Gateway DEST expression vectors.
Generation of mammalian expression vector backbones as Gateway DEST vectors.
Five custom Gateway fusion vectors were generated for mammalian cell expression using a pGEn2 vector backbone originally employed for the expression of rat ST6GalI 24 . This latter vector was generated by gene synthesis (Thermo Fisher Scientific) and contains a CMV promoter, an artificial intron, a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), and a bovine growth hormone (BGH) termination and polyadenylation sequence to drive transcription and termination of the fusion protein coding region. Each of the mammalian Gateway expression vectors was adapted for Gateway recombination as DEST vectors by inclusion of attR sites flanking a selection cassette comprised of ccdB and chloramphenicol resistance (Cm R ) genes 15 (Supplementary Fig. 2) . The fusion sequences in each of the five vectors were distinct, employing either NH 2 -terminal (pGEn1-DEST, pGEn2-DEST, and pGEn3-DEST vectors) or COOH-terminal (pGEc1-DEST and pGEc2-DEST vectors) fusion sequences adjacent to the selection cassette. Each vector component was generated by gene synthesis (Thermo Fisher Scientific) and swapped into the original synthetic ST6GAL1-pGEn2 vector as restriction fragments to replace the ST6GAL1 and adjoining fusion sequences. The pGEn1-DEST vector contains a Kozak sequence followed by an NH 2 -terminal signal sequence derived from the Trypanosoma cruzi lysosomal α-mannosidase 18 , an 8×His tag, and a StrepII tag 19 adjacent to the attR1 recombination site (Supplementary Fig. 2) . The pGEn2-DEST vector employs the same signal sequence and 8×His tag, but has an AviTag sequence 20 and a 'superfolder' GFP domain 21 adjacent to the attR1 recombination site (Supplementary Fig. 2) . The pGEn3-DEST vector has the same signal sequence, 8×His tag, AviTag and GFP tag as pGEn2-DEST, but also includes an immunoglobulin Fc domain 22 sequence between the GFP and the attR1 site ( Supplementary Fig. 2) .
For the pGEc1-DEST and pGEc2-DEST COOH-terminal fusion vectors the CMV promoter and artificial intron led directly to the attR1 site followed by the selection cassette (Supplementary Fig. 2) . For these vectors, the Kozak sequence and initiating Met residue were provided by the glycoenzyme donor clones. The fusion protein sequences for these vectors extend downstream of the attR2 site, where the pGEc1-DEST vector contained an 8×His tag and StrepII tag and the pGEc2-DEST vector contained a GFP domain, an AviTag sequence, and an 8×His tag (Supplementary Fig. 2) . Each of these selection cassettes and fusion sequences were generated by gene synthesis (Thermo Fisher Scientific) and swapped into the original ST6GAL1-pGEn2 vector as restriction fragments to replace the ST6GAL1 and adjoining fusion sequences.
Gateway recombination of donor clones into mammalian DEST vectors.
Transfer of the glycoenzyme coding regions from the donor vectors into the respective mammalian DEST expression vectors was accomplished using an LR Clonase reaction. Equal quantities of donor and DEST expression vectors were used for LR Clonase reactions (Thermo Fisher Scientific) according to the manufacturer's instructions. The reaction products were transformed into 5-alpha competent E. coli (New England BioLabs, Ipswitch, MA) and plated on LB plates containing ampicillin, and the resulting plasmid clones were screened by restriction mapping and verified by DNA sequencing of the entire coding region. Scientific) were maintained in suspension at 0.5-3.0 × 10 6 cells/mL in a humidified CO 2 platform shaker incubator at 37 °C using serum-free Freestyle 293 expression medium (Thermo Fisher Scientific). FreeStyle 293F cells were grown to a density of ~2.5 × 10 6 cells/ml and transfected by direct addition of 4.5 μg/ml of the respective expression plasmid DNA and 10 μg/ml polyethylenimine (linear 25 kDa PEI, Polysciences, Inc, Warrington, PA) to the suspension cultures as previously described 13 . The cultures were diluted 1:1 with Freestyle 293 expression medium containing 4.4 mM valproic acid (2.2 mM final) 24 h after transfection, and protein production was continued for another 4-5 d at 37 °C.
Small-scale transient transfection of mammalian expression vectors into HEK293 cells. FreeStyle 293F cells (Thermo Fisher
Construction of baculovirus-based Gateway DEST vectors.
Three different baculovirus DEST vectors were constructed for Gateway insertion of glycoenzyme coding sequences, as illustrated in Supplementary Figure 3 . Each comprised a baculovirus genome of ~135-140 Kbp lacking the viral chitinase and cathepsin-like protease genes with key genetic features added to their polyhedrin loci. Starting with orf603, which has the opposite orientation, the features of the NH 2 terminal tag fusions extending downstream in the 5′ to 3′ direction include the baculoviral polyhedrin promoter (pH), a Kozak consensus sequence, an ATG initiator codon, and sequences encoding either a 'short' tag consisting of the honeybee prepromellitin signal peptide 52 , an 8×His tag, and a StrepII tag, or a 'long' tag consisting of the same signal sequence and 8×His tag followed by an AviTag sequence and superfolder GFP domain followed by an attR1 site (short N-term fusion and GFP N-term fusion baculovirus DNAs, respectively, in Supplementary Fig. 3 ). The first attR1 site in both of these 'N-term tag fusion' vectors is followed by a herpes simplex virus 1 thymidine kinase gene, which is used for negative selection, and the E. coli β-galactosidase gene, which is used to identify parental virus clones after Gateway recombination, and these markers are followed by the second attR site (Supplementary Fig. 3) . In contrast, the baculovirus DEST vector designed for COOH terminal tag fusions includes the baculovirus orf603 and polh promoter followed directly by the thymidine kinase and β-galactosidase genes, which are flanked by attR sites (Supplementary Fig. 3 ). In addition, in this DEST vector, the downstream attR site is followed by sequences encoding a short tag consisting of StrepII and 8×His tags. Each of the baculovirus-based Gateway DEST vectors includes transcriptional termination signals located within the 3′UTR of the baculovirus polyhedrin gene, just upstream of orf1629 (Supplementary Fig. 3 ).
Gateway recombination of donor clones into baculovirus DEST vectors and isolation of recombinant baculovirus expression vectors.
The donor clones described above were used to insert sequences encoding glycoenzymes and TEV cleavage sites into the baculovirus DEST vectors by Gateway recombination. The encoded TEV cleavage sites were designed to appear on the COOH-or NH 2 -terminal sides of the tags encoded by the NH 2 terminal or COOH terminal tag fusion vectors, respectively. Gateway recombination was performed in LR Clonase (Thermo Fisher Scientific) reactions performed with a mixture of each donor plasmid and baculovirus DEST vector, according to the manufacturer's instructions. Following the addition of Cellfectin (Thermo Fisher Scientific) and a short incubation period, each LR reaction was used to transfect Sf9 cells seeded at a density of 0.8 × 10 6 cells/well into six-well plates. The cells were incubated for 5 h at 28 °C, and the transfection mixture was then removed and replaced by insect cell growth medium containing 100 μM gancyclovir. The cells were incubated for another 5 d at 28 °C for baculovirus progeny production with gancyclovir selection against the parental virus. Cell-free media containing these progeny were then harvested and used to isolate individual baculovirus clones by plaque assays in the presence of X-gal, as previously described 14 . After 7-10 d, at least three plaque purified (PP1) clones with white plaque phenotypes were picked and amplified in Sf9 cells, and the resulting PP1P1 virus stocks were assayed for glycoenzyme expression and secretion by immunoblotting with an anti-His tag antiserum, as previously described 14 . Once identified, samples of the PP1P1 baculovirus clones passing this screen were amplified to PP1P2 by infecting fresh Sf9 cell cultures, and the PP1P2 stocks were titered by plaque assay and finally used to document glycoenzyme production and secretion levels, as described below.
Recombinant glycoenzyme production in insect cells. Glycoenzyme production and secretion in the baculovirus-insect cell system was comprehensively documented by performing small-scale infections in Sf9 cells, as previously described 14 . Briefly, the cells were seeded at a density of 1 × 10 6 cells/well into six-well plates in a serum-free growth medium (ESF921; Expression Systems), then infected with individual baculovirus vectors at a multiplicity of infection of 5 plaque forming units/cell. At 48 h post-infection, the cells were scraped into the media, the cell-free media were harvested, and the cell pellets were boiled in SDS-PAGE sample buffer. Samples of the total cell lysates and cell free supernatants, which were also mixed with SDS-PAGE sample buffer and boiled, were then analyzed by SDS-PAGE with Coomassie blue staining or immunoblotting using PVDF membranes (Immobilon-P, Millipore, Billerica, MA) and an anti-His tag antibody (Thermo Fisher Scientific), as previously described 14 , to produce the results shown in Supplementary Figure 5b ,c.
We also performed midscale production runs in the baculovirus-insect cell system using a subset of BEVs encoding 20 different members of the GT29 sialyltransferase family. Briefly, Sf9 cells were seeded into 50 mL shake flasks in ESF921 and allowed to reach a density of ~1 × 10 6 cells/mL in a shaking incubator set at 125 r.p.m. and 28 °C. The cells were then gently centrifuged and each culture was infected with a BEV encoding a tagged sialyltransferase catalytic domain at a multiplicity of infection of five plaqueforming units/cell, as previously described 14 . At 48 h post-infection, the cellfree supernatant was harvested and ultracentrifuged to remove extracellular baculovirus and debris, and the resulting supernatant was used to affinity purify the secreted sialyltransferase products, as previously described 14 , except we used ProBond nickel chelating resin (Thermo Fisher Scientific). Finally, we analyzed samples of the cell free supernatants (starting material), unbound fraction (supernatants obtained after ProBond absorption), and elution fractions by SDS-PAGE with Coomassie blue staining or immunoblotting, as described above. In separate assays, we monitored GFP fluorescence in the starting material, flow through, and elution fractions, as described below.
Detection of recombinant glycoenzymes from HEK293 cells.
For small-scale screening of fusion protein expression in transiently transfected HEK293 cells, aliquots of the cell suspensions were harvested and subjected to direct GFP fluorescence measurement on a SpectraMAX GeminiXS microplate reader (Molecular Devices, Sunnyvale, CA) using an excitation wavelength of 450 nm and emission wavelength of 515 nm. The cultures were then clarified by centrifugation at 2,500 r.p.m. for 10 min in a microfuge and the supernatants were subjected to GFP fluorescence measurement as described above. Fluorescence values in the supernatants were subtracted from total culture fluorescence values to determine cell-associated fluorescence. A recombinant form of a GFP fusion protein was expressed, purified and used to derive a factor that was used to convert GFP fluorescence values to milligrams of recombinant protein.
Aliquots of the clarified cell supernatant and cell pellets were also boiled in SDS-PAGE sample buffer and analyzed by SDS-PAGE with Coomassie blue Crystallization and structure determination. Crystallization conditions for selenomethionine-labeled human ST6GalNAcII were initially screened using the high-throughput crystallization facility at the Hauptman Woodward Medical Research Institute 53 . Based on the results, the protein was crystallized using the microbatch method at 4 °C with a protein solution (2 μl) containing the enzyme (9.3 mg/ml) in a buffer consisting of 20 mM HEPES (pH 7.4), 200 mM NaCl, 60 mM imidazole, and recombinant peptide N-glycosidase (1:900) expressed in E. coli. The protein solution was mixed with 2 μl of the precipitant solution comprising 100 mM ammonium sulfate, 100 mM sodium citrate (pH 4.2), and 24% (w/v) PEG 20K. The crystals appeared after several days, and were harvested after one week, cryoprotected by supplementing the crystallization solution with 20% (v/v) glycerol, and flash-frozen in liquid nitrogen for data collection at 100 °K. A single-wavelength anomalous diffraction (SAD) data set to resolution 3.1 Å was collected at the peak absorption wavelength (0.9792 Å) of selenium at the 24-ID-E beamline of the Advanced Photon Synchrotron (APS). The diffraction images were processed with the HKL2000 package 54 . The crystals of the apo enzyme belong to space group P1, and there are six protomers in the asymmetric unit (ASU) of the crystal. The selenium sites were determined by the direct method using SHELX 55 , which located 23 of 30 possible selenium sites. The majority of the initial model comprising six protomers were manually built with the program XtalView 56 .
The selenomethionine-labeled ST6GalNAcII in complex with CMP was subsequently crystallized using the crystallization condition for the apo enzyme, except the protein solution contained 5 mM CMP. A singlewavelength native diffraction data set to resolution 2.35 Å was collected at the 14-1 beam line of the SLAC National Accelerator Laboratory. The diffraction images were processed with the HKL2000 package 54 . The crystals of the CMP complex also belong to space group P1, and there are six protomers per ASU of the crystal. The structure was determined using the molecular replacement method with the program COMO 57 . All stages of the structure refinement were performed using the crystallographic programs CNS 1.3 (ref. 58 ) and PHENIX 59 . PHENIX was also used in the last stage of refinement. The statistics for data collection and refinement are shown in Supplementary Table 3 .
Statistical analysis.
All expression studies were performed at least twice, and fluorescence values for the expression products in mammalian cells were ± 10% of the indicated values in each case. In Figure 3a , the bold red bar and error bars represent the mean and s.d. for the GFP fluorescence values relative to the qualitative values for baculovirus expression. The trend line in Figure 3a (red dotted line) is shown for the mean GFP fluorescence values. In Figure 3a , the black trend line represents a linear regression for a subset of the correlated fluorescence values (blue diamonds) comparing mammalian and insect cell expression for the human sialyltransferases.
Life sciences reporting summary. Further information on experimental design and reagents is available in the Life Sciences Reporting Summary.
Data availability. Atomic coordinates and structure factors for human ST6GalNAcII have been deposited in the Protein Data Bank under the following accession codes: apo-enzyme (6APJ) and CMP complex (6APL). Construct designs, annotations and sequences are summarized on our website (http://glycoenzymes.ccrc.uga.edu/). Plasmids are available from DNASU (https://dnasu. org) and baculovirus stocks are available from the Jarvis laboratory (dljarvis@ uwyo.edu). All data generated or analyzed during this study are included in this published article (and its supplementary information files) and from the corresponding author on reasonable request. staining or immunoblotting, as described above, except a mouse anti-poly-His tag antibody (Qiagen, Inc., Germantown, MD) was used.
Scale-up of recombinant glycoenzyme production in HEK293 cells for structural studies.
Recombinant enzyme production for protein structural studies was performed in a mutant HEK293 cell line defective in Asn-linked glycan maturation (HEK293S (GnTI -) cells 23 (ATCC)) using modifications of workflows based on prior structural studies on rat ST6GalI 24 . The HEK293S (GnTI -) cells were maintained at 0.5-3.0 × 10 6 cells/ml in a humidified CO 2 platform shaker incubator at 37 °C in cell culture medium comprised of 9 volumes of Freestyle 293 expression medium (Thermo Fisher Scientific) and 1 volume of Ex-cell 293 serum-free medium (Sigma; 9:1 medium). Transfections were accomplished by resuspending cells at ~2.8 × 10 6 cells/ml in fresh 9:1 medium, followed by direct addition of 4.5 μg/ml of the plasmid DNA (ST6GalNAcII-pGEn2) and 10 μg/ml polyethyleneimine to the suspension cell culture. The cultures were diluted 1:1 with 1:9 medium containing 4.4 mM valproic acid (2.2 mM final) 12-24 h after transfection, and protein production was continued for a further 4-5 d at 37 °C.
In cases in which recombinant proteins were labeled with selenomethionine (Sigma-Aldrich), cells were transfected as above, and the media were exchanged 12 h after transfection for custom methionine-free Freestyle 293 expression medium (Thermo Fisher Scientific) for 6 h to deplete methionine pools. The cultures were subsequently resuspended in methionine-free Freestyle 293 expression medium containing 60 mg/L selenomethionine at density of 2.0 × 10 6 cells/ml. The protein production was continued for 4-5 d at 37 °C before harvest of the conditioned medium.
Protein purification, deglycosylation, and tag removal employed workflows similar to prior structural studies on rat ST6GalI 24 . The conditioned culture medium was harvested, clarified by centrifugation, passed through a 0.45 μm filter (Millipore) and adjusted to contain 20 mM imidazole, 200 mM NaCl, and 30 mM sodium phosphate, pH 7.2, and loaded onto a 25 ml column of Ni 2+ -NTA Superflow (Qiagen, Valencia, CA) column equilibrated with 20 mM HEPES, 300 mM NaCl, 20 mM imidazole, pH 7.2. The column was washed with column buffer and eluted successively with column buffer containing 50 mM imidazole, 100 mM imidazole, and finally 300 mM imidazole. The 300 mM imidazole elution fractions were pooled and concentrated to 1 mg/ml using a 10 kDa molecular mass cutoff ultrafiltration membrane (Millipore, Billerica, MA). Purified recombinant TEV protease and EndoF1 expressed and purified as described 24 were added at ratios of 1:15 and 1:8 relative to the GFP-ST6GalNAcII, respectively, and incubated at room temperature for 3-5 h, followed by 4 °C overnight to cleave the tag and glycans. The protein mixture was diluted 15-fold in 50 mM sodium phosphate, pH 7.2, 800 mM NaCl, 10% glycerol to lower the imidazole concentration and loaded onto a 25 ml Ni 2+ -NTA column to remove the fusion tag and Histagged TEV protease and EndoF1. The unbound protein preparation was then concentrated by ultrafiltration and further purified on a Superdex 75 column (GE Healthcare) preconditioned with a buffer containing 20 mM HEPES, 200 mM NaCl, 60 mM imidazole, pH 7.2. Peak ST6GalNAcII fractions were collected and concentrated by ultrafiltration to 9-10 mg/ml for crystallization. Kinetic analysis. Sialyltransferase enzyme activity was measured using a phosphatase-coupled assay (malachite green phosphate detection kit, R&D Systems, Minneapolis, MN) essentially as previously described 24 , except asialofetuin was used as the acceptor. Assays were performed in a 50 μl reaction volume containing 100 mM MES, pH 6.5, 0.1 μg of recombinant ST6GalNAcII, CD73 (0.5 ng/μl), asialofetuin (250 μM for routine assays or varied from 25 to 800 μM for kinetic analysis), and CMP-Neu5Ac (250 μM for routine assays or varied from 25 to 1,000 μM for kinetic analysis). Following 30 min incubation at 37 °C, the reaction was stopped by addition of the malachite green phosphate detection reagents and, which was followed by further incubation as described by the manufacturer 24 . Absorbance at 620 nm was determined and compared with equivalent analyses for a phosphate standard curve. Enzyme activity values (nanomoles/min) were determined at varied substrate concentrations, and kinetic data were fit using GraphPad Prism software (version 5.00, La Jolla, CA) to determine K m and k cat values. 
Supplementary Figure 1. Strategy for cloning truncated and full-length glycoenzymes in Gateway donor vectors.
The strategy for PCR amplification of the truncated or full-length glycoenzyme coding regions is shown at the top of the figure, including primer designs for initial gene-specific amplification based on the truncation strategy described in Methods and Supplementary Tables 1 and Supplementary Data Sets 1 and 2. Enzymes with NH 2 -terminal truncations and fusions were amplified using gene specific primers to delete NH 2 -terminal sequences and initiate the addition of NH 2 -teminal primer-encoded extensions at the NH 2 -terminus comprising a TEV protease recognition site and COOH-terminal extensions comprising a Gateway attB2 recombination site following the enzyme's termination codon. A second round amplification was then performed using universal primers that completed the TEV recognition site and attB1 and attB2 recombination sites. The resulting PCR amplification products were then transferred to the Gateway pDONR221 vector by BP recombination (Glycogene-N-TermTEV-pDONR221, see Methods). A similar strategy was used to generate COOH-terminal TEV fusion constructs. In this case, the 5' genespecific PCR primers were designed to anneal at the ATG initiation codon and initiate the extension of an attB1 Gateway recombination site upstream of the Kozak sequence. The 3' gene-specific primers were designed to delete the termination codon (and, in some cases, additional upstream sequences to produce COOH-terminal truncations) and initiated the primer-encoded TEV protease recognition site. A second round amplification was then performed using universal primers to complete the TEV recognition site and attB1 and attB2 recombination sites. The resulting PCR amplification products were then transferred to the Gateway pDONR221 vector by BP recombination (Glycogene-C-TermTEV-pDONR221). The templates for the coding region PCR reactions were either human MGC clones encoding the respective genes or human tissue cDNA preparations (see Methods). In cases where gene-specific PCR amplification could not be achieved, the desired coding sequences with appropriate truncations, adjoining TEV protease recognition sites, and flanking attL recombination sites were generated by gene synthesis in vectors equivalent to pDONR221 (Glycogene-N-termTEV-pMK-RQ and Glycogene-C-termTEV-pMK-RQ). The library of NH 2terminal and COOH-terminal TEV fusion donor vectors were subsequently used for Gateway recombination reactions, resulting in transfer of the desired coding sequences into the desired eukaryotic DEST expression vectors (Supplementary Figs. 2 and 3 
Gene-specific 5'Primer Gene-specific 3'Primer
Supplementary Figure 2. Design strategy for NH 2 -terminal and COOH-terminal fusion vectors for expression in mammalian cells.
Multiple custom mammalian fusion vectors were designed with alternative NH 2 -terminal and COOH-terminal fusion tags. All the mammalian expression vectors contained a cytomegalovirus (CMV) promoter, woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), and a bovine growth hormone (BGH) termination and polyadenylation signal, and were adapted for Gateway recombination by inclusion of attR sites and a selection cassette to form DEST vectors as described in Methods. Distinctions between the vectors resulted from differences in fusion tag strategies. The pGEn1-DEST vector initiates translation with an NH 2 -terminal signal sequence, an 8xHis tag and StrepII tag as described in Methods. The pGEn2-DEST vector employs a signal sequence, 8xHis tag, AviTag, and GFP domain as described in Methods. The pGEn3-DEST vector included the same fusion tag components as pGEn2-DEST, but also included an Ig-Fc domain sequence as described in Methods. Gateway LR recombination of the glycoenzyme coding regions from the donor vectors into these pGEn DEST vectors results in the formation of an 8 amino acid recombination scar followed by the TEV cleavage site and the corresponding enzyme coding region. The COOH-terminal fusion vectors were analogous to the pGEn1 and pGEn2 vectors. In this latter case, the CMV promoter led directly to the attR1 site while the Kozak sequence and initiating Met residue were provided by the glycoenzyme donor clone. The COOHterminal fusion tags were appended downstream of the attR2 site in each vector. The pGEc1-DEST vector contained an 8xHis tag and StrepII tag and the pGEc2-DEST vector contained a GFP domain, AviTag sequence, and 8xHis tag. Gateway LR recombination of the glycoenzyme coding regions from the donor vectors into these latter pGEc DEST vectors results in the expression of the full-length protein coding region (or potential COOH-terminal truncation) followed by an 8 amino acid recombination scar, the TEV cleavage site and the respective fusion tags. . Each vector was adapted for Gateway recombination by inclusion of attR sites flanking a selection cassette as described in Methods. Distinctions between the vectors resulted from differences in fusion tag strategies. For vectors containing short NH 2 -terminal fusions, the coding region was initiated with a honeybee mellitin signal sequence, an 8xHis tag, and a StrepII tag. For longer NH 2 -terminal GFP fusions the vector employed the honeybee mellitin signal sequence, 8xHis tag, AviTag sequence, and GFP domain as described in Methods. Gateway LR recombination from the donor vectors into these baculoviral DEST vectors results in the formation of an 8 amino acid recombination scar followed by the TEV cleavage site and the corresponding enzyme coding region. A COOH-terminal baculovirus fusion vector was also generated analogous to the mammalian pGEc1 vector containing a StrepII tag and 8xHis tag downstream from the selection cassette. Gateway LR recombination from the donor vectors into this latter expression vector results in the expression of full-length protein coding regions (or potential COOH-terminal truncations) followed by an 8 amino acid recombination scar, the TEV cleavage site and the respective fusion tags. C generate conditioned media (Secreted, red or pink boxes) or cell pellets (Cell, dark blue or light blue boxes) and samples were resolved by SDS-PAGE. Gels were then either stained with Coomassie brilliant blue (Coomassie, red or blue boxes) or blotted and probed with an anti-His tag antibody (Blot, pink or light blue boxes). Recombinant products were detected in cell or media samples by immunoblots and in some cases by Coomassie staining. Most of the glycosylated sialyltransferase GFP fusion proteins were visible in blots and protein staining as ~55-75 kDa polypeptides with the exception of the ST6GalNAcI coding region, which is expressed as a ~110 kDa glycosylated fusion protein. The BEV 8xHis/StrepII expression products were ~32-50 kDa polypeptides except for the ST6GalNAcI coding region (~70 kDa). Immunodetection of cell-associated proteins in BEVS often revealed a ladder-like banding appearance that resulted from heterogeneity in glycosylation and potentially proteolysis. A sharper banding pattern was commonly found for the secreted products in the media of BEV cultures. In transfected HEK293 cell cultures, several sialyltransferase coding region products (ST6GalII, ST6GalNAcI, ST6GalNAcV, ST6GalNAcVI, ST8SiaI, ST8SiaII, ST8SiaIII, and ST8SiaIV) were apparently subject to partial proteolysis following secretion, since ~35-45 kDa His/AviTag/GFP bands were evident in the media in addition to the intact fusion proteins. Only the intact fusion proteins were detected in the cell pellets. with genes clustered by enzyme specificity subfamily (see Supplementary Fig. 8 ). GFP fluorescence values were also obtained for each fraction and are plotted at the top of each panel for the media (blue bars), column run-through (red bars), and elution (green bars) fractions. Most of the glycosylated sialyltransferase GFP fusion proteins were visible by protein staining as ~55-75 kDa polypeptides with the exception of the ST6GalNAcI coding region, which was expressed as a ~110 kDa glycosylated fusion protein. Figure 8 . Sequence alignment and secondary structures of mammalian sialyltransferases. The full length primary sequences all twenty human GT29 sialyltransferases and
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- human ST6GalNAcII, the present study; and human ST8SiaIII, PDB 5BO9 3 and ) were aligned using Coot 4 and the structures of the respective proteins were displayed as either a surface (Surface) or cartoon (Cartoon) representations of the GT-A (variant 2) Rossmann-like folds. Two orientations are shown for each protein, including a face-on view of the respective enzyme active site (Top View) or a Side View rotated 90°. The bound CMP donor analogs (ST3GalI, ST6GalI, and ST6GalNAcII) or CMP-Neu5Ac donor (ST8SiaIII) are shown with white stick representation in the respective structures. Bound glycan acceptor complexes were identified for ST3GalI, ST6GalI, and ST8SiaIII and the acceptor complexes are shown in cyan stick representation. A subset of each protein structure comprises the sialylmotif sequence elements (Supplementary Fig. 8 ) and these structural elements were extracted from the overall structures and are also shown in top and side views as a cartoon secondary structure representation. The sialylmotif elements comprise the scaffold that underlies the CMP-Neu5Ac binding site and the respective donor analog (CMP) or donor (CMP-Neu5Ac) is shown in white stick representation in association with each of the sialylmotif structures. The panels at the bottom of the figure show an overlay of the aligned structures and sialylmotif 
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